Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that Wild type KRAS, Wild type NRAS status confers therapeutic sensitivity to Cetuximab, Fluorouracil, Irinotecan in patients with Colorectal Adenocarcinoma.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of patients with RAS wild type metastatic colorectal cancer.